The estimated Net Worth of Sara Bonstein is at least $28 Million dollars as of 28 May 2024. Ms Bonstein owns over 241,288 units of Insmed Inc stock worth over $26,104,032 and over the last 11 years she sold INSM stock worth over $1,187,211. In addition, she makes $697,715 as Chief Financial Officer at Insmed Inc.
Ms has made over 15 trades of the Insmed Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 241,288 units of INSM stock worth $6,406,196 on 28 May 2024.
The largest trade she's ever made was exercising 241,288 units of Insmed Inc stock on 28 May 2024 worth over $6,406,196. On average, Ms trades about 3,642 units every 34 days since 2014. As of 28 May 2024 she still owns at least 358,769 units of Insmed Inc stock.
You can see the complete history of Ms Bonstein stock trades at the bottom of the page.
Sara M. Bonstein MBA is the Chief Financial Officer at Insmed Inc.
As the Chief Financial Officer of Insmed Inc, the total compensation of Ms MBA at Insmed Inc is $697,715. There are 9 executives at Insmed Inc getting paid more, with William Lewis having the highest compensation of $7,175,090.
Ms MBA is 40, she's been the Chief Financial Officer of Insmed Inc since . There are 22 older and 1 younger executives at Insmed Inc. The oldest executive at Insmed Inc is Steinar Engelsen, 70, who is the Independent Director.
Sara's mailing address filed with the SEC is C/O SCPHARMACEUTICALS INC, 25 BURLINGTON MALL ROAD, SUITE 203, BURLINGTON, MA, 01803.
Over the last 21 years, insiders at Insmed Inc have traded over $46,121,705 worth of Insmed Inc stock and bought 1,080,212 units worth $8,226,993 . The most active insiders traders include Llc Fmr, William Lewis und Dennis M Lanfear. On average, Insmed Inc executives and independent directors trade stock every 38 days with the average trade being worth of $2,452,158. The most recent stock trade was executed by Orlov S Nicole Schaeffer on 10 September 2024, trading 37,575 units of INSM stock currently worth $407,689.
insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. the company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. headquartered in bridgewater, nj, we are a rapidly growing company with offices in seven countries.
Insmed Inc executives and other stock owners filed with the SEC include: